Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The drug was approved by the US FDA in 2014 and by the EMA a year later for adults who are either obese or overweight with at least one weight-related condition
Previous observational studies have also linked GLP-1 treatment to a lower risk of alcohol and cannabis use disorders, opioid overdose, and alcohol related hospitalizations
The SURMOUNT-1 extension study found that participants who stopped tirzepatide regained approximately two-thirds of their lost weight within one year
Research published in the same journal in 2023 was used to support the MHRAs approval of Wegovy for lowering the risk of heart attack and stroke in people with heart disease and overweight or obesity
Telogen Effluvium and Androgenic Alopecia Rates High Among GLP-1 Receptor Agonist Users [Conference presentation]
US$ 21.67
US$ 23.87
US$ 23.92
US$ 22.88
US$ 29.70
